Clinical Trial

OH2 Injection in Solid Tumors

Completed Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-07
notable Enrollment increased: 30 -> 44 participants 2026-08-07
notable Primary completion pushed: 2026-03-13 -> 2026-06-02 2026-08-07
minor Completion moved earlier: 2026-12-13 -> 2026-06-02 2026-08-07
Trial Details
NCT Number NCT04386967
Lead Sponsor Binhui Biopharmaceutical Co., Ltd.
Conditions Solid Tumor, Melanoma
Enrollment 44 participants
Start Date 2018-11-22
Primary Completion 2026-06-02 (estimated)
Study Completion 2026-06-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06